By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


Start Up

Company News
Zafgen (ZFGN) Completes Enrollment Of Phase 2a Trial Of Beloranib In Hypothalamic Injury-Associated Obesity 9/25/2014 8:03:19 AM
Zafgen (ZFGN) To Present At 2014 Leerink Partners Rare Disease Roundtable 9/25/2014 7:40:00 AM
Frances K. Heller Rejoins Zafgen (ZFGN) Board Of Directors 9/18/2014 10:20:47 AM
Zafgen (ZFGN) Reports Second Quarter 2014 Financial Results 8/13/2014 4:01:05 PM
Zafgen (ZFGN) To Present At 34th Annual Canaccord Genuity Growth Conference 8/11/2014 5:22:28 PM
Zafgen (ZFGN) To Host Conference Call To Discuss Second Quarter 2014 Financial Results 8/7/2014 8:04:04 AM
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014 5:55:37 AM
Zafgen (ZFGN) Appoints Patrick Loustau As President 7/1/2014 8:54:41 AM
Zafgen (ZFGN) Appoints New Member Of Board Of Directors 6/27/2014 7:27:45 AM
Zafgen (ZFGN) Announces Closing Of Initial Public Offering And Full Exercise Of Over-Allotment Option 6/25/2014 8:42:25 AM